Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 370 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ΠΟΝΟΣ March 8, 2019 ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC November 23, 2021 Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in... September 27, 2024 ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... May 10, 2023 Load more HOT NEWS FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... A Nurse’s Love For Oncology Patients New option to treat advanced oesophageal cancer approved for NHS in... Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients...
